Literature DB >> 8024257

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

D Bravi1, M M Mouradian, J W Roberts, T L Davis, Y H Sohn, T N Chase.   

Abstract

Wearing-off phenomenon that complicates levodopa therapy of Parkinson's disease has been attributed to a reduction in striatal dopamine storage due to the progressive degeneration of presynaptic dopaminergic terminals. To determine whether postsynaptic mechanisms also contribute to these response fluctuations, the duration of the antiparkinsonian response in parkinsonian patients grouped by disease severity was compared following discontinuation of a steady-state optimal-dose infusion of apomorphine. Although the plasma half-life of this dopamine receptor agonist remained constant, its mean efficacy half-time declined from 66 minutes in early, levodopa-naive patients to 33 minutes in advanced, complicated parkinsonians (p < 0.005). Since the motor effects of apomorphine do not depend on the presence of dopaminergic terminals, changes at the postsynaptic level undoubtedly contribute to the diminished response duration. The only slightly greater attenuation of levodopa's motor effects observed previously under similar conditions suggests these postjunctional alterations, possibly involving relatively plastic striatal dopaminoceptive systems, account for most of the shortening in the duration of levodopa action that underlie wearing-off fluctuations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8024257     DOI: 10.1002/ana.410360108

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  23 in total

1.  Parkinson's Disease: Motor Fluctuations.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

2.  Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.

Authors:  A Fredriksson; N Schröder; T Archer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 3.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.

Authors:  C Colosimo; M Merello; A J Hughes; K Sieradzan; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

5.  Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.

Authors:  M Murata; H Mizusawa; H Yamanouchi; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.

Authors:  A Fredriksson; W Danysz; G Quack; T Archer
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

Review 7.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

8.  The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.

Authors:  Fulvio Bracco; Angelo Battaglia; Carlos Chouza; Erik Dupont; Oscar Gershanik; Jose Felix Marti Masso; Jean-Louis Montastruc
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Potential of transdermal drug delivery in Parkinson's disease.

Authors:  Ronald F Pfeiffer
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 10.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.